AI Article Synopsis
- A recent study examined the link between prescription medications, specifically prednisolone and warfarin, and the risk of developing oesophageal cancer using data from Scotland.
- A case-control study within the Clinical Practice Research Datalink found no significant increase in oesophageal cancer risk among users of either medication, even after adjusting for various factors.
- The findings suggest that oral prednisolone and warfarin do not contribute to the risk of developing oesophageal cancer, challenging earlier associations reported in some studies.
Article Abstract
Background: A recent epidemiological study systematically screened 250 prescription medications for associations with oesophageal cancer risk, using Scottish data, and identified an increased risk with use of prednisolone and warfarin. We investigated whether oral prednisolone or warfarin use was associated with increased oesophageal cancer risk.
Methods: A case-control study was conducted within the Clinical Practice Research Datalink. In the primary analysis oesophageal cancer cases were identified from linked cancer registry records. Up to 5 cancer-free controls were matched to each case (based upon sex, birth year, GP practice and year of GP registration). Prednisolone and warfarin medications were identified from prescribing records. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression after adjusting for covariates including demographics, comorbidities and medication use.
Results: There were 4552 oesophageal cancer cases and 22,601 matched control participants. Overall, there was no evidence of an increased risk of oesophageal cancer with oral prednisolone use (unadjusted OR=1.16 95% CI 1.06, 1.27 and adjusted OR=0.99 95% CI 0.89, 1.11) or warfarin use (unadjusted OR=1.12 95% CI 0.99, 1.28 and adjusted OR=1.08 95% CI 0.92, 1.27).
Conclusions: In this large population-based study, oral prednisolone and warfarin were not associated with oesophageal cancer risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canep.2024.102552 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Society of Thoracic Surgeons General Thoracic Surgery Database: 2024 Update on Outcomes and Research.
Ann Thorac Surg
January 2025
Division of General Thoracic Surgery, Departement of Surgery, University of California Davis Health, Sacramento, CA.
The Society of Thoracic Surgeons General Thoracic Surgery Database (STS GTSD) remains the largest and most comprehensive audited thoracic surgical database in the world. As the STS GTSD grows to nearly 1 million cases, the pulmonary resection for cancer and esophagectomy short-term risk models have been refined to provide participants with benchmarked performance reports to facilitate quality improvement efforts. New for 2025 will be the development of long-term risk models and the online release of both short- and long-term risk calculators.
View Article and Find Full Text PDFExploration of symptom cluster patterns and their trajectory in esophageal cancer surgery patients.
Eur J Oncol Nurs
January 2025
Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, PR China. Electronic address:
Purpose: To investigate symptom burden and symptom cluster trajectories in patients undergoing surgery for esophageal cancer.
Methods: A convenience sample of 210 patients who underwent thoracoscopic surgery for esophageal cancer was included from July to December 2023. The symptoms of the patients were evaluated at the following time points: preoperatively (T0), 1-3 days postoperatively (T1), 7 days postoperatively (T2), 1 month postoperatively (T3), and 3 months postoperatively (T4).
Estrogen Promotes the Proliferation and Migration of Endometrial Cancer Through the GPER-Mediated NOTCH Pathway.
J Biochem Mol Toxicol
February 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
This study aims to investigate the expression of GPER in EC, assess the impact of estrogen on the proliferation and migration of EC via GPER, and examine the potential role of GPER in mediating the NOTCH pathway to influence EC proliferation and migration. The expression of GPER and its correlation with clinicopathological features were investigated using clinical data. Cell proliferation was assessed through MTT and EdU assays, while cell migration ability was evaluated using wound healing and transwell assays.
View Article and Find Full Text PDFCharting the future of esophageal cancer translation: insights from clinical trial landscape.
Int J Surg
January 2025
Department of Radiotherapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, China.
Design, Synthesis and Anti-Inflammatory Evaluation of 3-Substituted 5-Amidobenzoate Derivatives as Novel P2Y Receptor Antagonists via Structure-Guided Molecular Hybridization.
J Med Chem
January 2025
College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
The P2YR is activated by UDP and UDP glucose and is involved in many human inflammatory diseases. Based on the molecular docking analysis of currently reported P2YR antagonists and the crystallographic overlap study between PPTN and compound , a series of 3-substituted 5-amidobenzoate derivatives were designed, synthesized, and identified as promising P2YR antagonists. The optimal compound (methyl 3-(1-benzo[]imidazol-2-yl)-5-(2-(-tolyl) acetamido)benzoate, IC = 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!